How much does Aidixi (Disitamab Vedotin For Injection) Cost& price without insurance in China?
Aidixi® is the domestic commercial brand name of Disitamab Vedotin For Injection, a domestically developed HER2-targeted antibody-drug conjugate (ADC) independently researched and developed by RemeGen. It consists of a humanized anti-HER2 monoclonal antibody conjugated with MMAE via a cleavable linker. The antibody specifically binds to HER2 on tumor cell surface, releasing cytotoxic MMAE inside tumor cells to block microtubule assembly and induce tumor cell death.
Main Indications
Treatment of locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) with HER2 overexpression, who have received at least two lines of prior systemic chemotherapy.
Treatment of locally advanced or metastatic urothelial carcinoma with HER2 overexpression who failed prior platinum-containing chemotherapy regimens.
Common Side Effects
Common mild adverse reactions: Peripheral sensory neuropathy, asthenia, decreased appetite, alopecia, elevated liver enzymes, diarrhea and nausea.
Laboratory abnormalities: Elevated transaminases, decreased leukocyte count and decreased neutrophil count.
Severe but uncommon risks: Severe peripheral neuropathy, severe myelosuppression, interstitial lung disease and infusion-related hypersensitivity reactions.
Approval Status in China
Aidixi® (Disitamab Vedotin For Injection, 60mg per vial) obtained conditional marketing approval in China in June 2021. It is the first China-originated ADC anti-tumor drug approved for marketing and is included in China’s Category B medical insurance catalogue.
Buy Aidixi (Disitamab Vedotin For Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
